N
5.50
0.04 (0.73%)
| Previous Close | 5.46 |
| Open | 5.62 |
| Volume | 52,042 |
| Avg. Volume (3M) | 65,222 |
| Market Cap | 139,070,416 |
| Price / Sales | 2.01 |
| 52 Weeks Range | |
| Earnings Date | 18 May 2026 |
| Operating Margin (TTM) | -93,965.52% |
| Diluted EPS (TTM) | -2.47 |
| Quarterly Revenue Growth (YOY) | -7.00% |
| Current Ratio (MRQ) | 0.410 |
| Operating Cash Flow (TTM) | -10.01 M |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | NeOnc Technologies Holdings, In | - | - |
AIStockmoo Score
0.5
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 0.50 |
|
NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration (FDA). |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 53.00% |
| % Held by Institutions | 0.31% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Cinctive Capital Management Lp | 31 Mar 2026 | 1,425,526 |
| Westmount Partners, Llc | 31 Mar 2026 | 43,320 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |